Identification of Immune Mediated Causes of Sensorineural Hearing Loss (R21/R33) | Apply Online

Opportunity Summary:

The grant opportunity titled "Identification of Immune Mediated Causes of Sensorineural Hearing Loss (R21/R33)" (Funding Opportunity Number RFA-DC-11-002) is a National Institutes of Health (NIH) program run through the National Institute on Deafness and Other Communication Disorders (NIDCD). It is designed to push forward research on immune mediated sensorineural hearing loss (IMSNHL), with a clear emphasis on understanding what causes it, how it develops, and what biological mechanisms drive the damage that ultimately affects hearing. The overall goal is practical and clinically focused: generate findings that can be translated into real-world tools such as biomarkers and diagnostic tests that perform well (high sensitivity, high specificity, and strong positive predictive value), and ultimately support the development of treatments that protect or preserve natural hearing.

The scientific scope is intentionally targeted at immune-related forms of sensorineural hearing loss. The announcement highlights three areas that are considered responsive. First are studies focused on ear organ-specific autoimmune sensorineural hearing loss, commonly referred to as autoimmune inner ear disease (AIED). Second are studies of sudden sensorineural hearing loss when it can be attributed to AIED, which speaks to rapid-onset cases where immune activity may be the trigger or driver. Third are studies looking at sensorineural hearing loss that occurs in connection with systemic autoimmune diseases, where the immune dysfunction is not limited to the ear but may involve broader inflammatory or autoimmune processes affecting multiple organs. In other words, the program is interested both in immune attacks that appear confined to the inner ear and in hearing loss that shows up as part of larger autoimmune conditions.

A central feature of the program is the priority it gives to human-centered research. Proposals that primarily involve human subjects or human tissues are stated to receive the highest priority. That emphasis signals that the institute wants studies that are close to clinical reality, such as work using patient samples, clinically characterized cohorts, or tissue-based investigations that can directly inform diagnostics and treatment strategies. While basic and mechanistic questions are still part of the mission, the framing makes it clear that the preferred path is one that can bridge the gap between laboratory insights and clinical use.

In terms of funding structure, this opportunity uses the NIH R21/R33 Exploratory/Developmental Phased Innovation mechanism. This is a milestone-driven, phased approach: the R21 phase typically supports early, exploratory, or developmental work, and the R33 phase supports a subsequent stage that builds on success in the first phase. The milestone-driven language matters because it implies applicants are expected to define concrete, measurable goals and decision points that justify moving from the initial exploratory phase into the more advanced phase. The intent is to support innovative, interdisciplinary projects while keeping them accountable to progress markers that show the work is on track and ready for expansion.

The funding levels and award expectations are spelled out in the announcement. NIDCD set aside approximately $700,000 for fiscal year 2011 and $1.3 million for fiscal year 2012. The institute anticipated making about 2 to 3 awards per application cycle, indicating a competitive program with a limited number of funded projects, likely focused on proposals with clear milestones and a strong translational line of sight toward diagnostics, biomarkers, and therapeutic development.

Administrative details further define who can apply and how the program is categorized. The opportunity is listed as a discretionary grant under the health activity category, associated with CFDA number 93.173 (Research Related to Deafness and Communication Disorders). There is no cost sharing or matching requirement, meaning applicants are not required to contribute non-federal funds as a condition of the award. The posting and creation date for the opportunity was August 18, 2010, with an original and final closing date of June 8, 2011, and an archive date of July 9, 2011, which indicates the opportunity is now historical rather than currently open.

Eligibility is broad and spans a wide range of organization types. Eligible applicants include small businesses, for-profit organizations (including those other than small businesses), public and private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), state governments, U.S. territory or possession entities, and a variety of tribal organizations (including federally recognized tribal governments and other tribal entities). The eligibility language also explicitly includes several institution categories and community-based organizations, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, and even non-U.S. entities (foreign organizations). Federal agencies are also listed among eligible applicants, reflecting NIH rules that sometimes allow intramural or federal participation depending on the specific terms.

Taken together, the opportunity is essentially a call for interdisciplinary, milestone-oriented projects that can explain immune-driven hearing loss in humans and move the field toward better clinical detection and intervention. It is not just about describing associations; it is about identifying mechanisms and measurable indicators that can become reliable clinical tools, and about laying the groundwork for therapies that can prevent hearing loss from progressing or preserve existing hearing in people affected by autoimmune or immune-mediated processes. For reference, the full announcement was hosted by NIH at: http://grants.nih.gov/grants/guide/rfa-files/RFA-DC-11-002.html.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Conduct accuracy assessments of completed vegetation mapping

Previous opportunity: Diagnosis and Management of Severe Febrile Illness

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA DC 11 002

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA DC 11 002) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA DC 11 002", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.